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ABSTRACT
In disease states such as cancer, endocrine and paracrine signals from adipose tissue
contribute to cancer progression and drug resistance. Young individuals diagnosed with
estrogen receptor-alpha positive (ER-a+) breast cancer have an observed increase in
resistance to endocrine therapies. This suggests that an alternative estrogen signaling
pathway is active within these tumors. Despite this, the effects of stromal age on the
endocrine response in breast cancer is not well known. Here, we review and highlight the
involvement of the stromal age in both tumorigenesis and physiological wound healing.
To identify specific differences between young and aged ER-a+ breast tumors, RNA
sequencing data was obtained from The Cancer Genome Atlas (TCGA). Analysis
revealed enrichment of matrix and paracrine factors in young (<40 years old) patients
compared to aged (>65 years old) tumor samples. Analyzing cell infiltrate of young and
aged ER-a+ breast tumors revealed significant differences in several immune cell
populations, however, there were no differences in MSC and adipocyte infiltrate between
young and aged tumors. Based on these results, we next sought to determine if stromal
cells exhibited age-dependent differences. To determine if the age of tumor stroma
differentially regulated the ER-a+ tumor microenvironment (TME), adipose-derived
stem/stromal cells (ASCs) from healthy young and aged donors were evaluated for
alterations in matrix production and paracrine factors. Results demonstrated that young
and aged ASCs were neither phenotypically different, nor did they demonstrate
alterations in matrix production. Analysis of paracrine factors demonstrated that young
and aged ASCs had differences in pro-inflammatory cytokines. Paracrine factors from
young ASCs enhanced the ER-a regulated genes progesterone receptor (PR) and
stromal-derived factor 1 (SDF-1) in the MCF-7 ER-a+ breast cancer cell line. Additionally,
western blot analysis demonstrated increased activation of p-ER ser167 in the MCF-7
cell line treated with young ASC paracrine factors. These results are important in
understanding the mechanisms of estrogen receptor signaling in young breast cancer
patients, as well as unveiling underlying factors that contribute to the unique TME in young
breast cancer patients.
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CHAPTER 1. BACKGROUND AND SIGNIFICANCE
1.1 Breast Cancer and Tumor Microenvironment
Breast cancer is a heterogeneous disease that includes several biological subtypes
that exhibit different clinical behaviors and treatment responses1. These tumors express
the estrogen receptor (ER) and/or progesterone receptor (PR). Together, these comprise
the luminal subtype and represent approximately ~70% of all breast cancer cases2, 3.
Hormone receptor positive breast cancer can be further subdivided into luminal A and
luminal B. Luminal A accounts for 30-40% of all invasive breast cancers, whereas luminal
B accounts for 20-30%4. Other subtypes of breast cancer include human epidermal
growth factor receptor 2 (HER2) enriched and basal-like/triple negative (Table 1.1). The
presence of PR in breast tumors is an important indicator for endocrine therapy
responsiveness and ER function5, 6.

Table 1.1. Classification of molecular subtypes of breast cancer. Table reproduced from
data from Fragomeni et al., 2018.

1.1.1 ER-a+ Breast Cancer: Biology and Treatment Options
Estrogen plays an important role in the development and progression of breast
cancer. ER is one of the most significant prognostic biomarkers in breast cancer and
possesses a dual role as both a nuclear hormone receptor and transcription factor. ER
has two subtypes: ER-a and ER-b. ER-a is present mainly in mammary glands, uterus,
bone, male reproductive organs, and liver. On the other hand, ER-b is expressed mainly
in the bladder, colon, and the immune system7. Both subtypes are expressed in
adipose, prostate, and ovarian tissue. The activation of the ER-a receptors are
responsible for most estrogen effects on normal breast tissue and cancerous breast
tissue, leading to hormone-dependent tumor growth8, 9. ER-a can be activated via
classical estrogen ligand-binding or through a complex network of tyrosine kinase
membrane receptors and their downstream targets (Fig 1.1). The classical mechanism
of estrogen signaling is also known as direct genomic signaling. Upon binding to
1

estradiol, the nuclear estrogen receptor ER-a behaves as a transcription factor and
translocates from the cytoplasm to the nucleus10, 11. The complex then binds to estrogen
response elements (EREs) on or within close proximity to promoters on chromatin12.

Figure 1.1. Estrogen receptor (ER) signaling pathway. (a)
Classic ER signaling (b) The ER activation through
receptor tyrosine kinases (RTKs) (c) Nongenomic functions
of ER. Figure reproduced with permission from Macmillan
Publishers Ltd.: Musgrove and Sutherland, 2009.
Receptor tyrosine kinases (RTKs) including epidermal growth factor receptor (EGFR),
insulin-like growth factor 1 receptor (IGF1R), and HER2 can stimulate ER translocation,
thus regulating gene expression and controlling cell growth, proliferation, and survival13.
The non-genomic function of ER-a and its ability to bind to and activate transcription
factors adds to the complexity of ER-a signaling. The non-genomic actions of estrogen
lead to a more rapid signaling response. After the discovery of the G Protein-Coupled
Estrogen Receptor (GPER1), a membrane bound estrogen receptor that induces a fast
estrogen-mediated activation of extracellular signal-regulated kinases (ERKs), the
mechanism of estrogen expanded beyond direct target gene transcription and protein
synthesis14, 15. The non-genomic actions of estrogen involve the activation of several
protein-kinase signaling cascades including: the phospholipase C (PLC)/protein kinase
C (PKC) pathway, RAS/RAF/MAPK cascade, phosphatidyl inositol 3 kinase (PI3K)/AKT
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kinase cascade, and cAMP/protein kinase A (PKA) signaling pathway16-21. These
signaling pathways subsequently activate transcription factors such as the nuclear
factor-kappa B (NF-kB) complex, which translocates to the nucleus and to their cognate
DNA binding sites. Estrogen receptors can also be activated in the absence of
estrogens or receptor agonists via a ligand-independent signaling mechanism22-25.
Activation occurs via phosphorylation of specific residues (i.e. serine or tyrosine) on the
receptors or by association with coregulators. The coregulators encompass a variety of
regulatory molecules including PKA, PKC, MAPK cascade components, inflammatory
cytokines (IL-2), cell adhesion molecules (Heregulin), cell cycle regulators (RAS), and
peptide growth factors (EGF, IGF-1, TGFb)25. ER-a activation and signaling is best
interpreted through ER-a response genes. PR is an important target gene of ER-a and
thus behaves as a downstream indicator of estrogen action26. Similar to ER-a, there is
also extensive crosstalk between PR and signal transduction pathways that are not only
required for mammary gland development, but are also often elevated in breast cancer.
Historically, PR was thought to be a tightly regulated target of ER-a; however, studies
have shown that growth factors such as IGF-1 downregulate PR activity through the
PI3K/AKT/mTOR signaling pathway independent of ER-a activity27. Furthermore, the
downregulation of PR activity signifies increased growth factor activity28. The ER-a
independent function of PR and the complex crosstalk of multiple signal transduction
pathways with ER-a and PR increase the difficulty to provide targeted therapy for breast
cancer patients.
In ER-a+ breast cancers, active ER-a signaling drives cell proliferation, thus
making ER-a heavily exploited as the target for treatment. Inhibitors of the ER-a pathway
are categorized based on their mechanism of action: 1) compounds that decrease
endogenous estrogen production (aromatase inhibitors-AI and gonadotropin-releasing
hormone agonists or 2) compounds that directly antagonize ER-a (selective estrogen
receptor modulators and selective estrogen receptor degraders-SERMs and SERDs)29.
Despite their positive therapeutic effect on ER-a+ breast cancers, many of the ER-a
antagonists have become ineffective due to endocrine resistance. A large number of
patients with ER-a+ breast cancers do not respond to endocrine therapy either due to de
novo or acquired resistance13, 30-32. As described above, many different factors including
growth factors, cytokines, and estrogens may contribute to and induce ER-a signaling
cascades. The complexity of endocrine signaling makes it difficult to define, identify the
root causes, and generate alternative treatment options. Clinical studies have described
several mechanisms for the resistance to endocrine therapies33, 34. The variance in
mechanisms makes the treatment strategy increasingly difficult and dependent on the
context. The impact of the tumor microenvironment (TME) plays a significant role in the
development and progression of breast cancer and is a contributing source for many of
signaling molecules that can modulate ER-a signaling. It should be considered as a key
player in the development of endocrine response and resistance in breast cancer
patients.
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1.1.2 The Tumor Microenvironment (TME)
The TME is a heterogeneous network consisting of different cellular types and
extracellular components. The cellular and extracellular network communicates with the
tumor cells, creating an intricate signaling system. The “seed and soil” hypothesis
suggests that the host microenvironment (the soil) is required for optimal growth of the
tumor cells (the seed)35. This hypothesis has driven a shift from primary focus on the
tumor cells to the characterization and analysis of the interactions of the tumor stroma
with the tumor cells. The communication between the host stroma and tumor cells
drastically impacts tumor growth and progression. Dvorak describes tumors as “wounds
that do not heal” and emphasizes the similarities of normal wound healing to tumor
stromal generation36. Similar to the phases of wound healing, tumor stromal generation
exhibits neoangiogenesis, infiltration of fibroblasts and immune cells, and remodeling of
the extracellular matrix (ECM) (Table 1.2). Tumors recruit supporting cells from the local
host stroma which promote ECM remodeling, cellular migration, neoangiogenesis,
invasion, drug resistance, and evasion of immunosurveillance through the production of
growth factors, chemokines, and cytokines37. Supporting cells include fibroblasts,
myofibroblasts, endothelial cells, adipocytes, mesenchymal stem cells (MSCs), and
various immune cells38-40. The infiltration of the cellular recruits is in response to tumordriven inflammation41. Chronic inflammation aids in shaping the TME and has been
referred to as a host reaction to the tumor; however, it is more appropriate to characterize
this response as a tumor promoting reaction41. A contributing factor to the inflammatory
nature of the tumor infiltrates is the self-induced hypoxic environment. Early in tumor
development, tumor cells activate hypoxia-responsive genes, which in turn stimulate the
influx of inflammatory cells into the TME. Hypoxia activates the NF-kB signaling pathway,
which plays a key role in signaling of cancer cells and tumor-infiltrating leukocytes42-44.
NF-kB activation leads to the secretion of tumor necrosis factor-alpha (TNF-a) and other
pro-inflammatory cytokines that drive the expression of cytokine genes responsible for
cell proliferation. In response to the pro-inflammatory cytokine cascade, tumor and
stromal cells produce a wide array of biological mediators that help maintain the cell
proliferation and differentiation, matrix remodeling, neoangiogenesis, and cell
migration/recruitment necessary for tumor growth. MSCs, one of the supporting cell
populations of the tumor stroma, are of particular interest in the development and
progression of breast cancer because of their release of cytokines and growth factors that
enhance the inflammatory nature of tumors.
Some MSCs, such as ASCs, have a natural proclivity to induce inflammation
because their tissue of origin, adipose tissue, actively participates in physiologic and
pathologic processes including immunity and inflammation. As the largest endocrine
organ, adipose tissue releases a variety of pro-inflammatory and anti-inflammatory factors
including the adipokines leptin (LEP) and adiponectin (ADIPOQ), as well as cytokines
and chemokines such as TNF-a, interleukin 6 (IL-6), and monocyte chemoattractant
protein 1 (MCP-1)45. Further discussion of the effect of MSCs on breast cancer
development and progression is presented in section 1.2.
The TME and its stromal cell population heavily influences breast cancer initiation
and growth; however, several key elements are missing from the picture. Included within
this is the effect of patient demographics. Studies have examined the role of body mass

4

index (BMI) on the TME and breast cancer progression, but have yet to consider the role
of other patient demographics including age on the nature of the TME46, 47. The
characterization of MSCs based on age and the role it plays in breast cancer development
and progression has yet to be fully elucidated.
1.2 Breast Cancer and Stem Cells
As previously described in section 1.1, the tumor stroma is composed of a
heterogeneous cell population that includes MSCs. The secretion of factors such as MCP1 and SDF-1 from the tumor’s cancer and inflammatory cell population recruits MSCs to
the TME. After recruitment to the site of inflammation, MSCs become part of the tumor
stroma and facilitate tumor growth. Studies have shown that MSCs not only stimulate
tumor growth, but also promote angiogenesis and increase cancer cell invasion48-50.
Breast cancer cell-activated MSCs secrete a large panel of cytokines, chemokines, and
growth factors that in turn enhances breast cancer cell proliferation in an MSC/breast
cancer cell reciprocal feedback loop51. The dynamic relationship between MSCs and
cancer cells not only influences tumor growth, aggressiveness, and metastatic spread,
but may also function as barrier for therapeutic intervention in breast cancer patients.
1.2.1 Adipose-Derived Stem/Stromal Cell Biology
ASCs, a subset of mesenchymal stem cells isolated from adipose tissue, have
gained clinical interest due to both their abundant and readily available resources, and
because of their similarity to other established stem cell lines52. ASCs possess the ability
to self-renew and differentiate toward adipogenic, osteogenic, and chondrogenic lineages
in response to specific stimuli52-55. ASCs promote damaged tissue recovery by
proliferating and differentiating cells; however, their capacity to supply growth factors and
cytokine to tissue repair may be of even greater importance56. Studies have shown that
ASCs are superior in secretion of bioactive factors that may stimulate cell proliferation,
differentiation, and migration of cell types including fibroblasts, endothelial cells, and
epithelial cells57. ASCs release a wide range of trophic factors including chemokines,
growth factors, pro-inflammatory cytokines, anti-inflammatory cytokines, and pro-
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Table 1.2. Trophic and immunomodulatory factors secreted by MSCs. Table
reproduced from data from da Silva Meirelles et al., 2009 and Kochan et al., 2017.

angiogenic/anti-apoptotic/anti-scarring factors56, 58 (Fig 1.2, Table 1.2). Hsiao et al. found
that out of all MSC populations, ASCs were the most optimal for promoting angiogenesis
and had higher levels of insulin like growth factor 1 (IGF-1), vascular endothelial growth
factor D (VEGF-D), and hepatocyte growth factor (HGF)59, 60. These growth factors have
both angiogenic and anti-apoptotic properties and are associated with endothelial cell
growth and survival61. In addition to growth factors, ASCs also secrete a variety of
cytokines and chemokines. Many of the secreted cytokines including interferon gamma
(IFN-g), IL-1b, IL-17, IL-8, and TNF-a are pro-inflammatory in nature62. Other MSCsecreted inflammatory chemokines including MCP-1 and CCL5 promote tumor
aggressiveness and support tumor-supporting effects in TME cells. Furthermore, these
chemokines play a pivotal role in the growth and metastasis of cancers, including breast
cancer60, 63-67. Previous studies have shown that stromal-derived factor 1 (SDF-1),
another ASC-secreted chemokine, is not only an important mediator of ASC chemotaxis,
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Figure 1.2. Paracrine effects of cultured MSCs. The secretion of a
broad range of bioactive molecules is now believed to be the main
mechanism by which MSCs achieve their therapeutic effect and it can
be divided into six main categories: immunomodulation, anti-apoptosis,
angiogenesis, support of the growth and differentiation of local stem
and progenitor cells, anti-scarring and chemoattraction. Figure
reproduced with permission from da Silva Meirelles et al., 2009.

but it is also contributes to primary breast tumorigenesis and promotes hormone
independent growth of the hormone-dependent breast carcinoma cell line MCF-768-70. In
contrast to a tumorigenic role, IL-8, MCP-1, CCL5, and SDF-1 are also targeted to
improve wound healing. IL-8 acts as a potent neutrophil attractant during the early stages
of wound healing71. ASCs also release CCL5 and MCP-1, which recruits macrophages to
the wound site72. In the proliferation phase of wound healing, ASCs secrete SDF-1 to
recruit more ASCs to the site, which then differentiate into endothelial cells and fibroblasts
to form the granulation tissue73, 74. Similar to ASCs, “tumor wounds” secrete cytokines
and chemokines that aid in myeloid cell recruitment. After reaching the tumor site, many
of these myeloid cells differentiate into immunosuppressive and angiogenic phenotypes
that help to facilitate tumor growth. This prevents tissue restoration and allows the tumor
to remain in the proliferative phase of the wound healing process. Analogous to a tumor,
the chemokine and cytokine milieu released by ASCs can also instigate the formation of
a non-healing “tumor wound”. The dual nature of ASCs as both regenerative and prooncogenic has earned them their reputation as a “double-edged sword”75, 76. Despite their
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therapeutic potential, ASCs also pose a risk for the development and progression of
tumors, as well as the recurrence of different types of cancer77-79 Studies have shown that
ASC paracrine signaling plays a crucial role in the breast cancer TME and aids in tumor
progression.
1.3 Cancer and Wound Healing
1.3.1 Parallels between Cancer and Wound Healing
Aging entails the progressive, generalized impairment of physiological function,
resulting in a poor response to environmental challenges and expanding risk of disease
and death. Although susceptibility to chronic diseases such as cancer and impaired
wound healing increases with age, the potency of wound and cancer response appears
to be far greater in younger individuals. Studies have shown that younger individuals
experience more aggressive cancers with lower survival rates in both breast and
colorectal cancers80-83. The physiological wound healing response occurs via a tightly
regulated series of overlapping phases involving numerous cell types, tissues, secretory
factors, and proteolytic enzymes. Tumors, which can be characterized as an
unconventional, non-healing wound, hijack the body’s wound response to create an ideal
environment for tumor growth and progression. Studies have shown that all major
pathways activated in wound healing are also active in cancers84-87. A study by Chang et
al. revealed that the gene expression pattern of serum-treated fibroblasts exhibiting a
wound healing response parallels that of human carcinomas88. Molecular features that
characterize the wound-like phenotype are observed at an early clinical stage, persist
during treatment, and predict risk of metastasis and death in breast, lung, and gastric
carcinomas88 89, 90. Riss et al. have shown that 77% of genes expressed in a model of
renal repair and regeneration were also expressed in renal cancer. Many of these genes
are active pathways common to cancer and repair including cell proliferation, growth,
metabolism, and defense.91 In a study by Groessl et al., cancer-associated fibroblasts
from breast cancer biopsies displayed a wound healing signature92. Multiple sources have
emphasized that inflammation, an essential phase of the wound healing response, is a
key player in cancer progression84, 93, 94. An overabundance of specific inflammatory cell
types, as discussed in detail below, results in the transformation of an acute wound into
a chronic wound, and non-cancerous tissue into tumors95-97. Similar to a wound, tumors
also secrete various trophic factors that aid in the recruitment of multiple cell types
including MSCs.
1.3.2 Stromal Contribution to Cancer and Wound Healing
BMSCs and ASCs respond to damaged tissues and organs and secrete cytokines,
chemokines, and growth factors to mediate the physiological wound healing response98100
. The therapeutic effect of MSCs during wound repair can be attributed to the release
of these trophic factors, which promote angiogenesis, cell recruitment, differentiation,
proliferation, and ECM formation101-103. Kilroy et al. characterized the cytokine profile of
MSCs showing that the use of the pro-inflammatory ligand lipopolysaccharide (LPS), an
immune stimulating glycolipid produced by gram-negative bacteria. Results from this
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study demonstrated that MSCs released angiogenic HGF and VEGF, and hematopoietic
(IL-7, GM-CSF)) cytokines, in addition to secreting a number of pro-inflammatory
cytokines (IL-6, IL-8, IL-11, TNF-a)104. The paracrine behavior of MSCs also poses both
immunomodulatory and immunosuppressive effects that impacts the wound healing
process. As a response to both injury and inflammation, the release of prostaglandin E2
(PGE2) by MSCs results in the upregulation of interleukin 10 (IL-10) and decrease in
TNF- a and interleukin 12 (IL-12) secretion from dendritic cells, leading to a shift from a
more pro-inflammatory Th1 subtype to an anti-inflammatory Th2 subtype105. MSCs
attenuate the release of inflammatory mediators from macrophages and modulate the
proliferation, differentiation, and immunoglobulin secretion of B cells105-107. The release of
cytokines that both support and delay tissue recovery pose many questions concerning
the role of MSCs in wound healing and tumorigenesis. Evidence has shown that MSCs
not only aid in the healing of conventional wounds, but are also linked to non-healing
tumor wounds. Similar to wound response, MSCs respond to tumors by homing to the
tumor site to mediate the physiological wound healing response. Both newly recruited
and resident MSCs work together to accelerate the tumor “wound healing”108. Similar to
their role in physiological wound healing, MSCs assist in regulating tumor-associated
immune responses. After instruction by the TME, MSCs secrete cytokines and
chemokines that exaggerate tumor-associated inflammation via the recruitment of
multiple immune cell types109-113(Table 1.3). In addition to inducing inflammation, MSCs
can also suppress the adaptive immune response in the TME through the release of
effector molecules including nitric oxide (NO) and indoleamine 2,3-dioxygenase (IDO)114118
. Although there is a substantial body of work dedicated to the role of BMSCs in wound
healing and tumorigenesis, ASCs and their impact on wound healing and tumorigenesis
will be the sole focus of this dissertation. For more information regarding BMSCs, please
refer to the following articles119-121.

Table 1.3. The effect of MSCs on immune cell infiltrate.
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1.3.3 The Impact of Aging on Cancer and Wound Healing
Age has been hypothesized as a significant contributing factor in both wound
healing and cancer, yet few studies have focused on the characterization of MSCs on the
basis of age. As illustrated by Dvorak, the tumor response has striking similarities to the
physiological response to tissue injury85. Based on this relationship, age could play a
crucial role in both responses. Young individuals exhibit a more exuberant wound healing
response compared to aged. The impact of aging is observed in all phases of the wound
healing process122. The disruption of any step in one of the phases in wound repair can
lead to a 20-60% delay in healing123. Fully understanding the dynamic interplay of stromal
age and wound healing response could offer insight into why young patients with some
cancer subtypes present with a poorer prognosis and greater mortality than aged124. In
this dissertation, we investigated the role of MSCs in the physiological wound healing
process, their response to non-healing tumor wounds, and the impact of age on the MSC
response to both wound types.
1.4 ASC Response to Tumors and Wounds
1.4.1 Physiological Wounds Vs. Tumor Wounds
The wound healing process is characterized by a dynamic series of overlapping
phases involving numerous cell types, tissues, cytokines, chemokines, growth factors,
and proteolytic enzymes125. Cellular activities including proliferation, migration, and ECM
synthesis are tightly regulated in the wound healing phases of hemostasis (coagulation),
inflammation, proliferation (formation of granulation tissue), and tissue remodeling (scar
formation)126, 127 (Fig. 1.3). Hemostasis is characterized by fibrin clot formation, platelet
activation, and release of inflammatory mediators. The release of numerous cytokines,
chemokines, and growth factors including PDGF, transforming growth factor A1 (TGFA1), and TGF-2 promotes the migration of inflammatory cells such as leukocytes,
neutrophils, and macrophages to the wound site. The inflammatory phase, characterized
by the infiltration of neutrophils and macrophages, is crucial in supplying growth factor
and cytokine signals that are responsible for cell migration and subsequent tissue repair95,
128
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Figure 1.3. Cytokines released during the phases of acute wound healing are also
present during cancer hallmark acquisition. (A) Tissue injury activates platelet recruitment
to the site of injury, where a temporary fibrin clot stops blood vessel hemorrhage. Platelets
release a heterogeneous mix of growth factors and cytokines (PDGF, TGF-b, IL-8, SDF1, CXCL4, bFGF, VEGF) that aid in the repair process. (B) The inflammatory phase
begins with the influx of neutrophils followed by macrophages to the wound bed.
Neutrophils begin the phagocytosis of debris in the wound and release chemokines
(MCP-1 and CCL5) that recruit macrophages to the wound. With the reduction of
neutrophils around days 2-4, macrophages become the dominant inflammatory cells in
the wound. They not only protect the wound from foreign microorganisms, but they also
release growth factors, chemokines, and cytokines (VEGF, bFGF, PDGF, TNF-a) that aid
in wound repair. (C) Around days 3-10, fibroblasts are recruited to the wound, where they
contribute to the formation of a temporary ECM. (D) Several months to years after injury,
cells leave the wound or undergo apoptosis, ECM is broken down by matrix
metalloproteinases (MMPs) and metalloproteinase tissue inhibitors (TIMPs). Type III
collage that was deposited during the proliferation phase is degraded and replaced by a
more permanent Type I collagen. Growth factors and cytokines highlighted in the 4
phases of wound healing are also actively involved in the hallmarks of cancer outlined by
Hanahan and Weinberg (2011). Parallels in secreted factors of wound healing are
observed in the following cancer hallmarks: tumor and repair promoting inflammation,
sustaining proliferative signaling, and angiogenesis. The color scheme linking the
association between the hallmarks of cancer and specific paracrine factors can be
referenced using the figure legend. This figure was created using BioRender.com.
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Neutrophils release a variety of inflammatory cytokines including TNF-a, IL-1b, and IL-6,
IL-8, and MCP-1, which not only amplify the inflammatory response but also stimulate the
release of VEGF and IL-8 to further enhance the repair response. Macrophages are
described as key regulators in the response because of their roles in debris removal,
promotion and conclusion of inflammation, and secretion of cytokines and growth factors
for recruitment and activation of other cells involved in the repair process. The proliferative
phase entails the replacement of temporary fibrin matrix with granulation tissue via
fibroblast-driven ECM deposition. Growth factors produced by remaining inflammatory
cells and migrating epidermal and dermal cells maintain cell proliferation and initiate cell
migration to the wound bed. In response to the hypoxic wound environment, a robust
angiogenic response is initiated and sustained by the production of VEGF, fibroblast
growth factor 2 (FGF2), and PDGF by platelets and resident cells. In the final phase of
remodeling, ECM components undergo multiple steps of degradation and synthesis to
restore normal tissue architecture. The vascularization process initiated during the
previous phase provides a favorable environment for continued epidermal and dermal
cell migration and proliferation. This leads to wound re-epithelialization and restoration of
epidermal integrity. Fibroblasts proliferate within the wound and synthesize ECM, which
is initially composed of collagen III, fibronectin (FN1), fibrin, and hyaluronic acid. The initial
matrix is then substituted with ECM mainly composed of collagen I. After wound
contraction and matrix remodeling, fibroblasts undergo apoptosis and leave a relatively
acellular scar that is comparable to the unwounded skin. The previous overview of the
wound healing process strictly applies to acute wounds. Unlike acute wounds, chronic
wounds exhibit prolonged or excessive inflammation, inability of dermal and epidermal
cells to respond to reparative stimuli, or persistent infections (Fig. 1.4). Chronic wounds,
including diabetic ulcers, pressure ulcers, and vascular ulcers, are all characterized by a
chronically inflamed wound bed and failure to heal129. Although the differences between
ECM composition of acute and chronic wounds is both minimal and controversial, studies
have shown that chronic wounds are characterized by either prolonged or poor
expression of fibronectin, chondroitin sulfate, and tenascin. This leads to impaired cell
proliferation and migration129. Glycation, the attachment of sugars to matrix proteins, also
contributes to matrix instability and disrupts interactions between collagen and its binding
partners as observed in aging129. In chronic wounds, an excessive recruitment of
inflammatory cells that produce various reactive oxygen species (ROS) results in the
damage of ECM structural elements and cell membranes, leading to premature cell
senescence129. Increased levels of matrix metalloproteinases (MMPs) also contributes to
the degradation of ECM and inhibition of new ECM deposition130. In conjunction with proinflammatory cytokines, ROS induces the production of enzymes that degrade and
inactivate ECM components and growth factors necessary for normal cell function.
Although chronic wounds exhibit an observed increase in growth factors compared to
acute wounds, both their quality and bioavailability are compromised in chronic wounds.
In addition to excessive inflammation chronic wounds also display impaired angiogenesis
and neovascularization, which subsequently leads to insufficient oxygen and nutrient
supply to cells within the wound bed. Similar to a physiological wound, tumors activate
the same multi-step process to aid in growth and progression.
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Normal tissues are comprised of two components, the parenchyma and stroma. The
stroma, a mixture of fixed tissue cells, inflammatory cells, blood vessels, matrix proteins,
and proteoglycans, provides support to the parenchyma. Tumor composition is analogous
to normal tissue, organized into the parenchyma (malignant cells) and stroma. Solid
tumors such as carcinomas or sarcomas attain semblance to healing wounds by
exploiting the host vascularized tissue stroma for survival, growth, and metastasis131-135.
Troester et al. have shown that a wound response signature is activated in histologically
normal tissue of breast cancer patients90. The overlapping phases of blood clotting,
inflammation, extracellular matrix alterations, angiogenesis, and tissue remodeling are
expressed in normal tissue adjacent to breast cancer and in tumors, further solidifying
similarities between tumors and physiological wounds84, 136. The hallmarks of wound
healing also parallel some of the hallmarks of cancer86. Out of the ten hallmarks of cancer,
three of the hallmarks have close ties with the four phases of wound healing. Secretory
factors observed in wound healing are also observed in cancer. Many of these factors are
observed in multiple phases of wound healing and actively participate in multiple wound
healing phases including TGF-b, VEGF, PDGF, basic fibroblast growth factor (bFGF),
TNF-a, and IL-8 (Fig 1.3). One type of tumor that embodies the nature of malignant
tumors and chronic wounds is the keloid scar. Keloid scars are characterized as benign
human tumors without malignant potential that exhibit elevated matrix deposition and
chronic inflammation137. Previously, keloids were characterized by an overabundance of
disorganized type I and III collagen bundles138. Fibroblasts in keloids exhibit an altered
phenotype of intrinsic or growth factor stimulated collagen, fibronectin, elastin, and
proteoglycan accumulation139. Current studies have shown that new keloid lesions
demonstrate elevated matrix protein expression of collagens (COL1A1, COL6A1,
COL10A1, COL11A1, COL12A1), FN1, and fibrillin-2 (FBN2) compared to non-lesion
tissue140, 141. Many of these same matrix components are observed to be elevated in triple
negative breast cancer (TNBC) compared to matched non-diseased breast adipose
tissue. TNBC is void of ER, PR, and HER2, characterizing it as a more aggressive breast
cancer type. Previous studies have evaluated the matrix composition of TNBC compared
to distal adipose tissue and observed elevated protein levels of COL6A1, COL11A1,
COL12A1, FN1, and FBN2, with a minor increase in COL1A1140. Similar data was
observed by others who profiled 13 TNBC samples compared to adjacent adipose
tissue140. Another link between keloids and cancer progression is plasminogen activator
inhibitor 1 (PAI-1). In in-vitro 3D culture, keloid fibroblasts show elevated collagen
accumulation and altered fibrin degradation. PAI-1, a major inhibitor of plasminogen
activators that are responsible for the conversion of plasminogen to plasmin, is thought
to be linked with poor fibrin degradation observed in keloids99. For proper repair in the
wound healing process, the temporary fibrin matrix must be degraded and replaced by
fibroblast-synthesized collagen. In addition to organ fibrosis, PAI-1 also plays a role in
tumor progression. Not only is it highly expressed in tumor biopsies, but it is also
prognostic for disease progression and relapse in certain cancer types, one in particular
being breast cancer142. PAI-1 can induce tumor vascularization, promote cell
dissemination, and tumor metastasis142. Keloid-derived fibroblasts have been shown to
exhibit elevated expression of transforming growth factor-b1 (TGFb-1) and transforming
growth factor-b2 (TGF-b2)141, 143. TGFb has profound effects on PAI-1 upregulation in
tissue and organ fibrosis. TGFb increases production of ECM molecules by cells and
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slows down their removal by upregulating protease inhibitors (TIMP1 and PAI-1) and
downregulating protease (MMP1 and uPA) expression139. Elevated TGFb-1 in
hepatocellular carcinoma and breast, lung, and prostate cancer patients correlates with
poor outcome144. In breast cancer, TGFb-1 exhibits a dual role as both tumor suppressive
and oncogenic in nature. In early stages of breast cancer, TGFb-1 shows tumor
suppressive effects by inhibiting epithelial cell cycle progression and promoting apoptosis.
However, in the late stages of breast cancer, TGFb-1 is correlated with increased tumor
progression, higher cell motility, cancer invasiveness, and metastasis145. Interestingly,
with respect to patient age, the expression TGF-b, a growth factor responsible for the
stimulating the synthesis of collagen and promoting wound healing, is markedly reduced
in aged individuals compared to young146, 147. Similar to TNBC, keloid scarring has a
higher prevalence in African Americans and in individuals between the age of 10 and
30148, 149. Age and race appear to be common factors between keloid scarring and the
more aggressive cancer subtypes such as TNBC. Data suggests that breast cancer in
young women (<40 years old) have a poorer prognosis and higher mortality compared to
breast cancers diagnosed in older women150, 151. Furthermore, young African American
women (<40 years old) are more likely to be diagnosed at younger ages with a more

Figure 1.4. Chronic wounds exhibit similarities to tumors. Acute wounds exhibit
adequate angiogenesis that aids in fibroblast proliferation, re-epithelialization, and
neutrophil infiltration. On the other hand, chronic wounds exhibit poor angiogenesis,
elevated neutrophil infiltration, persistent bacterial infections, and decreased fibroblast
proliferation. Higher infiltration of inflammatory cells leads to the excessive secretion of
inflammatory markers, which leads to growth factor and ECM degradation. The chronic
inflammation also prevents macrophage polarization from an inflammatory to antiinflammatory phenotype, which prevents resolution of the wound and maintains it in a
non-healing state. Similar to chronic wounds, tumors also exhibit higher neutrophil and
macrophage infiltrate, increased levels of pro-inflammatory cytokines, and ECM
degradation as a result of inflammation. Unlike chronic wounds, tumors increase
collagen synthesis. This figure was created using BioRender.com.
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aggressive TNBC subtype152, 153. The commonalties between keloid scarring and TNBC
may offer more insight into the role of age in tumorigenesis. To date, commonalities
between age and TNBC has been established; however, the extent to which age impacts
the ER-a+ subtype and TME has yet to be fully elucidated.
1.4.2 ASCs: Their role in the physiological wound and TME
Adipose tissue is a viable source of stromal/stem cells that exhibit both
multipotency and immunomodulatory characteristics154-156. The regenerative capacity of
ASCs is harnessed through their secretome157, 158. ASCs secrete a wide variety of growth
factors, cytokines, adipokines, neurotrophic factors, adipokines, and angiogenic factors
such as PDGF, FGF, VEGF, HGF, SDF-1, IL-6, IL-8, transforming growth factor alpha
(TGF-a) and angiopoietin159-162. In vivo, ASCs reside in the stem cell niche, where they
are surrounded by the ECM and other supporting cells163. The stem cell niche or more
commonly referred to as the microenvironment, modulates the ability of ASCs to
differentiate, proliferate, and migrate as they aid in the restoration of cellular age defects
and tissue repair164. In response to injury, ASCs have been shown to shift the
inflammatory phenotype of local immune cells to a more anti-inflammatory phenotype via
soluble factors165. ASCs alter the inflammatory profiles of macrophages, T cells, B cells,
and dendritic cells, which in turn furthers the proliferative and remodeling phases of the
wound healing process166, 167. Many of these soluble factors described above are also
associated with expressing and/or secreting multiple growth factors, cytokines,
chemokines, and inflammatory markers that are linked to cancer development and
progression168-176. ASCs promote the recovery of wound blood via the secretion of
angiogenic factors. VEGF is the most important angiogenic growth factor because of its
ability to promote endothelial progenitor cell mobilization, recruitment, and migration,
which accelerates angiogenesis in the wound177. Heo et al. determined that TNF-a
activated ASCs produce pro-inflammatory cytokines IL-6 and IL-8 aid in angiogenesis and
epithelium regeneration in wound repair178, 179. Interestingly, high serum levels of both IL6 and IL-8 correlated with strong tumor invasion and poor prognosis in breast cancer180.
In addition to VEGF, many angiogenic factors including PDGF and angiopoietin are
secreted throughout several phases of the wound healing process181. Although beneficial
during wound repair, both VEGF and PDGF aid in endothelial cell proliferation and
vascularization of tumors181. TNF-a, a pro-inflammatory cytokine involved in systemic
inflammation, is secreted by both ASCs and tumor cells. TNF-a is upregulated in the
inflammatory phase of wound healing. ASCs stimulate macrophages to secrete TNF-a,
which further aids in activation, proliferation, apoptosis, and differentiation of other
macrophages. TNF-a secreted by ASCs has been associated with the development of
the tissue architecture necessary for tumor growth and metastasis182. In addition, long
term exposure of hormone receptor positive (HR+) breast cancer cells to TNF-a results in
epithelial to mesenchymal transition (EMT) and a more aggressive phenotype182. In
physiological wound healing, ASC-secreted IL-6 aids in macrophage recruitment and M1
to M2 polarization164. Studies have exhibited that chronic inflammation associated with
excessive IL-6 secretion facilitates tumor development182. MCP-1, another proinflammatory cytokine produced by ASCs, promotes macrophage recruitment during
wound healing. Similar to previously mentioned mediators, MCP-1 is also involved in
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breast cancer tumor progression and metastasis182. LEP, an adipokine secreted by ASCs,
stimulates angiogenesis, cell proliferation and differentiation, and migration of
keratinocytes to enhance wound healing182. LEP also plays a crucial role in
tumorigenesis. In HR+ breast cancer, LEP is correlated with higher recurrence rates and
increased invasiveness76. LEP also increases TNF-a expression, ROS production, MCP1 expression, and endothelial cell proliferation and migration, all of which increase cancer
cell growth and mobility182. As previously mentioned in terms of keloid formation, PAI-1
contributes to proper wound healing through the breakdown of the fibrin clot. Studies have
shown that ASC-secreted PAI-1 has been associated with tumor cell invasion and
metastasis, as well as a poor prognostic indicator in breast and colon cancers182.
Circulating levels and protein content of growth differentiation factor 11 (GDF11), a
member of the TGF-b superfamily, is affected by pathological conditions and age183. It
has a role in multiple phases of the wound healing process by increasing cell proliferation
and migration, angiogenesis, and ECM production164. Studies on the effect of GDF11 and
cancer progression are inconclusive. Some studies have shown that GDF11 induces
tumor suppressive properties, while others indicate GDF11 promotes tumorigenesis183.
Similar to GDF11, TGF-b1 is active in multiple steps of the wound healing process. TGFb1 plays the role of a paracrine mediator that activates fibroblasts, macrophages, and
ASC secretions164. In breast cancer, TGF-b1 enhances progression of breast
malignancies into more malignant phenotypes76. Increased expression of the chemokine
SDF-1 by ASCs amplifies ASC migration to the wound site164. SDF-1 has also been noted
as an important factor in the spread of breast cancer cells76. SDF-1 and its receptor,
chemokine receptor type 4 (CXCR4), play an important role in HR+ breast cancer70. The
expression of SDF-1-CXCR4 is associated with the EMT phenotype. Furthermore,
crosstalk between ER-a, SDF-1, and CXCR4 contributes to hormone independence,
making it increasingly difficult to treat with endocrine therapy70. Although these specific
soluble mediators have roles in both wound healing and tumorigenesis, the question
arises concerning how their roles are altered by aging. Many of the regenerative qualities
of ASCs including proliferation and differentiation capacity change with age. The ASC
secretome has been harnessed as a viable treatment option for chronic non-healing
wounds, however studies have yet to characterize the ASC secretome as a function of
age184. Several of the aforementioned mediators including PDGF, VEGF, IL-6, TNF-a,
SDF-1, TGF-b1, and LEP are affected by aging125(Table 1.4). Although little evidence
suggests ASC-secreted PDGF is impacted by age, studies have shown that aging results
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Table 1.4. Paracrine Factors Observed in Wound Healing and Tumorigenesis. Asterisk
(*) indicates information was provided by a review article.
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in the enhanced release of PDGF, TGF-b, and TGF-a from a-granules125. Increased age
also correlates with a decline in phagocytic activity of wound macrophages, leading to an
accumulation in IL-6 and TNF-a125. In contrast, Pandey et al. revealed that aged ASCs
exhibit lower expression of TNF-a relative to young ASCs. This suggests that the impact
of aging on each cell type is distinct. Aging may have different effects on immune cells
compared to tissue-derived cells such as ASCs. VEGF, an essential regulator of
angiogenesis, has exhibited a decline in expression with aging125. In contrast, studies
have shown that ASC-secreted VEGF levels is unaffected by age when active in bone
healing185. Aging also results in a decrease in SDF-1 expression in wound healing,
however there is no evidence suggesting that age affects ASC production of SDF-1125.
Hypoxia plays a significant role in the physiologic wound healing process186. With aging,
wound response to hypoxia diminishes, thus responsiveness to TGF-b1 also diminishes.
In normal tissues, TGF-b1 increases the deposition of collagen by stimulating its
synthesis and minimizing its degradation. In aged wound tissue, this ratio of synthesis to
degradation is imbalanced125. The adipokine LEP not only promotes wound healing, but
it also plays an oncogenic role in breast cancer187, 188. In a study by Pandey et al., LEP
expression in aged ASCs was significantly lower compared to young ASCs189. With
elevated levels in young ASCs and links to both wound healing and tumorigenesis, LEP
could be a potential target underlying amplified tumor aggressiveness observed in young
patients. Based on this investigation, paracrine factors have an extensive role in wound
healing and tumorigenesis regardless of ASC involvement. We have knowledge that
ASCs secrete the paracrine factors listed in Table 1.4, however, we can only speculate
that ASCs releasee these factors in response to wound repair and tumorigenesis. ASCs
are also recognized as playing a pivotal role in both wound healing and tumorigenesis.
The extent to which age impacts the role of ASCs in both of these pathologies is not well
understood. Studies on aging and cutaneous wound healing have highlighted changes in
many of these secreted factors. While these factors are ASC associated, these changes
have not yet been linked specifically to ASCs.
1.4.3 Adipose-Derived Stem/Stromal Cells and ER-a+ Breast Cancer
As previously described in section 1.1.2, the interaction between ASCs and the
TME has adverse effects on breast cancer development and progression. Based on a
review by Freese et al., numerous studies have been conducted to determine the role of
ASCs in human breast cancer development, growth, progression, and metastasis169. The
duality of ASCs as both regenerative and tumorigenic in nature makes their role in tumor
development extremely complex. Many studies have suggested that the ability of ASCs
to release pro-migratory factors may influence their role in cancer169, 190-193. Others have
suggested ASCs play an important role in pathologic angiogenesis and formation of a
blood supply for the growing tumor194. Crosstalk between ASCs and breast cancer cells
diminishes the efficacy of hormonal therapy195. To date, the full impact of ASCs on the
TME is yet to be established and may have confounding results due to differences in
patient demographics that influence ASC function.
Patient characteristics such as BMI can alter ASC function and the stimulatory
effect on ER-a+ breast cancer. In non-cancerous tissue, obesity increases the expression
of pro-inflammatory factors such as IL-6, IL-1, IL-12, PDGF, TNF-a, leukemia inhibitory
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factor (LIF), and granulocyte-colony stimulating factor (GSF)196. Strong et al. discovered
that LEP from obese ASCs (BMI greater than or equal to 30 kg/m2) promoted ER-a+
cancer growth and metastasis compared to those of a healthy BMI (18.5-24.9 kg/m2) 197,
198
. LEP indirectly increases estrogen synthesis and ER-a activity by upregulating
aromatase expression and activity in ER-a+ breast cancer cells199. ASCs exhibit an innate
ability to drive ER-a+ breast cancer through aberrant paracrine signaling. In the absence
of cell-cell contact, ASCs are able to increase the proliferation of MCF-7 cells70. This
evidence suggests ASCs not only behave as protagonists in ER-a+ breast cancer, but
also complicate treatment efforts. Their homing and immunomodulatory functions in
observed in the wound healing and tissue regeneration process also appears to prime
and transform sites into suitable environments for tumor growth199, 200. As presented in
this dissertation, ASCs may play a similar role in ER-a+ breast cancer and wound healing
response. The body of evidence investigating ASCs from this perspective is still sparse;
however, there is considerable amount of evidence focusing on BMSCs and their role in
wound healing and cancer progression108. Many of the cytokines and growth factors that
have been presented in section 1.4.2 as potential links between ASCs and the tumor
wound have been previously cited in epithelial stem cells lines201. With this said, more
short-term experiments focusing on the ASC secretome’s impact on wound healing and
tumorigenesis need to be conducted to bridge this gap in knowledge. Rather than
generalizing, studies need to focus on specific cancer types and specific ASC
demographics.
1.5 Overview of Research
This dissertation is divided into three specific aims that focuses on the characterization of
stromal age and breast cancer, specifically the impact of adipose-derived stem/stromal
cells on regulation of endocrine signaling. These aims are designed to test the overall
hypothesis that the young ASC secretome contributes to elevated estrogen signaling in
ER-a+ breast cancer.
Aim 1: Characterization of ER-a+ breast cancer tumors of young and aged patients.
This aim is designed to determine differences in young and aged breast cancer tumors
based on gene expression and resident cell population. Data acquired from The Cancer
Genome Atlas (TCGA), GenEx Miner, Kaplan Meier plotter was used to investigate gene
expression as a function of tumor age. TCGA and GenEx Miner was used to compare the
gene expression of ER-a+ breast cancer tumors from aged and young patients. Kaplan
Meier plotter was used to determine the impact of significant genes observed in the former
platforms on the survival rate of ER-a+ breast cancer patients. xCell cell type enrichment
analysis was implemented to characterize the cell infiltrate of young and aged tumors.
Aim 2: Characterization of young ASCs. This aim was designed to evaluate young
ASC phenotype. To determine the impact of ASCs on the stromal environment, we
compared the proliferation, differentiation, matrix gene expression, and cytokine
expression of young and aged ASCs. The proliferation and differentiation capacity of
young and aged ASCs was assessed on tissue culture plastic. Matrix gene expression of
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young and aged ASCs was evaluated using qRT-PCR. The secretome of young and aged
ASCs was compared using cytokine array analysis.
Aim 3: Identify the role of the ASC secretome on ER-a+ breast cancer estrogen
activity. This aim was designed to assess how the young ASC secretome affects ER-a+
breast cancer. The MCF-7 ER-a+ breast cancer cell line was exposed to conditioned
media (CM) acquired from young and aged ASC donors and assessed for differences in
proliferation and estrogen signaling. Proliferation of MCF-7 cells stimulated with young
and aged CM was evaluated using Crystal Violet staining. Differences in estrogen
signaling was compared in MCF-7 cells stimulated with young and aged CM using qRTPCR and Western Blot Analysis.
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CHAPTER 2. THE CHARACTERIZATION OF YOUNG ASCs
2.1 Introduction
Aging is notably characterized as a progressive, generalized impairment of
function, resulting in a poor response to environmental challenges and expanding risk of
disease and death. Two of the many chronic diseases associated with aging are cancer
and impaired wound healing. Wound healing occurs via a complex, coordinated series
overlapping phases involving numerous cell types, tissues, cytokines, chemokines,
growth factors, and proteolytic enzymes. The cellular activities including migration,
proliferation, phagocytosis, and ECM synthesis are tightly regulated. The wound repair
program follows the chronological order of hemostasis, inflammation, proliferation, and
tissue remodeling to ensure optimal repair126. Tumors, an unconventional, non-healing
wound, hijack the body’s wound repair program, creating an ideal environment for tumor
growth and progression. Similar to a wound, tumors secrete factors that aid in the
recruitment of multiple cell types including MSCs.
MSCs, derivatives of mesenchymal tissues including bone marrow and adipose
tissue, display a propensity to migrate toward damaged tissues and organs where they
then secrete cytokines to mediate wound healing98-100. The therapeutic effect of MSCs
can be attributed to the release of these cytokines that promote new vessel formation,
recruit endogenous cells, and direct cell differentiation, proliferation, and ECM formation
during wound repair101-103. Kilroy et al. characterized the cytokine profile of MSCs (mean
age 37.8 yo +/- 10.6, BMI 25.4 kg/m2) showing that lipopolysaccharide (LPS)-stimulated
MSCs not only release angiogenic (HGF, VEGF) and hematopoietic (IL-7, GM-CSF)
cytokines, but also secrete a number of pro-inflammatory cytokines (IL-6, IL-8, IL-11,
TNF-a)104. The release of cytokines that both support and delay tissue recovery pose
many questions concerning the role of MSCs in wound healing. Evidence has shown that
MSCs not only aid in the healing of conventional wounds, but are also linked to the
“wounds that never heal” observed in cancer. Age is a significant factor in both wound
healing and cancer, yet few studies have focused on the characterization of MSCs on the
basis of age. Previous studies have demonstrated that key demographic factors such as
age and diseased states can alter stem cell biology202, 203. Modifications to the underlying
biology of stem cells can result in an altered response to diseased states such as nonhealing wounds and cancer. In this study, we investigated the effect of age on ASC
function. We compared the proliferation, differentiation, matrix deposition, and paracrine
secretions of aged and young ASCs. Through an age-dependent characterization of
ASCs, we intended to determine which ASC characteristics may impact the features
observed in young ER-a+ breast cancer tumors.
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2.2 Materials and Methods
Cell Culture:
Cell Source: Human adipose-derived stem/stromal cells (ASCs) were obtained from
Obatala Sciences (New Orleans, LA). Young donors (24-34 years old, mean age 27.8 +/4.1 SEM) and aged donors (60-70 years old, mean age 62+/- 7.8 SEM) matched
according to corresponding body mass indices. All donors were female and Caucasian
(Table S1).
ASC Culture: Cultures of ASCs (3,000 cells/cm2) were maintained with Alpha-MEM with
L-glutamine (Cat #: 12561-056, Gibco) supplemented with 10% fetal bovine serum (FBS,
Cat #: 43602-500, JR Scientific) and 1% Antibiotic-Antimycotic (Anti-Anti, Cat #15240062,
Gibco) until attained 80% confluence. The procedure implemented for ASC expansion
was described previously by Bunnell et al 204. Cells were then seeded at 2,000 cells/cm2
in 6-well plates, 3,000 cells/cm2 in 96-well plates, 3,000 cells/cm2, and 2,000 cells/cm2 in
60 x 15 mm plates for qRT-PCR, immunostaining, proliferation, and differentiation assays.
For coated ECM, aged and young ASCs were seeded at 3,000 cells/cm2 on laminin (Cat
#: 354533, Corning) and fibronectin (Cat #: 354532, Corning) coated 25 cm2 flasks and
maintained at 5% CO2 at 37°C until attaining 80% confluent and cells were collected for
qRT-PCR.
Adipogenic Differentiation: Cultured ASCs were detached, counted, and seeded in 6-well
plates at 2,000 cells/cm2. Three days after plating, cells were induced using adipogenic
differentiation medium (Cat #: OS-002-01, Obatala Sciences), changing medium every 3
days for 14 days. Cells were then washed 3x with Phosphate Buffer Solution (PBS, Cat
#: 10010-023, Gibco) and fixed for 1 h with 10% formalin. Fixative was then removed and
cells were washed 3x with PBS prior to staining with 0.5% Oil Red-O. After staining for 1
h, wells were washed 3x with PBS and imaged using an inverted fluorescence
microscope (Olympus IX-81, Olympus Corporation) and NIS Elements Microscope
Imaging Software (Nikon).
ASC Proliferation: Cultured ASCs were detached, counted, and seeded in 96-well plates
at 3,000 cells/cm2 . Three days after plating, wells were maintained with culture medium
(Alpha MEM with L-glutamine,10% FBS, and 1% Anti-Anti) or induced with osteogenic or
adipogenic differentiation medium. Cell density at days 1, 3, 7, and 10 was assessed
using the Cell Counting Kit-8 (CCK-8, Dojindo). Absorbance was measured using a cell
imaging multimode reader (Cytation 3, BioTek) and Gen5 Microplate Reader and Imager
Software (BioTek).
Immunofluorescent Staining: Cultured ASCs were seeded in 96-well plates at 3,000
cells/cm2 and maintained in culture medium for 24 h. Cells were then fixed with 10%
formalin for 15 min, washed with PBS 3x, and permeabilized with 0.5% (v/v) Triton 100X for 10 min. After removing the detergent, cells were washed 3x with PBS and blocked
with 0.1% (w/v) BSA in PBS for 1 h. With the removal of the blocking agent, cells were
stained with 100 µL of Alexa Fluor 488 phalloidin for 30 min at room temperature (Cat
#A12379, Invitrogen). This was proceeded by washing 3x with PBS and staining with 100
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µL of DAPI diluted 1:300 in 0.1% (w/v) BSA for 10 min at room temperature (Cat#:
157574, MP Biomedicals). Cells were then washed 3x with PBS and imaged using an
inverted confocal fluorescence microscope (Leica SP8, Leica Microsystems) and Leica
Application Suite X (LASX, Leica Microsystems).
Quantitative Real-Time Polymerase Chain Reactions (qRT-PCR): ASCs were collected
and total RNA was extracted with Quick RNA MicroPrep kit (Cat #: R1051, Zymo
Research) as per manufacturer protocol. cDNA was synthesized using qScript cDNA
SuperMix (Cat #: 101414-106, VWR), as per manufacture protocol with 1µg RNA per
sample. Primer was obtained using Primer-BLAST software (NCBI). Primer sequences
are presented in Table S2. Quantitative real-time PCR (qRT-PCR) was performed using
the BioRad iCycler (BioRad, v4.006). Expression was computed using the comparative
cycle threshold (Ct) method using the reference gene GAPDH. Normalization of young
donor gene expression was to aged donor gene expression designated as 1.
Cytokine array analysis: ASCs were cultured until attained 80% confluency in 10% AlphaMEM with L-glutamine (Cat #: 12561-056, Gibco) supplemented with 10% fetal bovine
serum (FBS, Cat #: 43602-500, JR Scientific) and 1% Antibiotic-Antimycotic (Anti-Anti,
Cat #15240062, Gibco). Cells were washed with sterile phosphate buffer saline (PBS,
Cat #: 10010023, Gibco). ASCs were then cultured in phenol-free Dulbecco’s modified
Eagle’s medium (Cat #:31053-028, Gibco), 5% charcoal stripped FBS (Cat #:
SH3006803, GE Healthcare), 1% penicillin/streptomycin (P/S, Cat #: 15140-122, Gibco),
1% MEMAA, 1% NEAA, 1% Glutamax (Cat #: 35050-061, Gibco), and 1% sodium
pyruvate for 24 h. The conditioned media was collected, filtered, and stored at -20°C for
cytokine array analysis. The cytokine array analysis procedures followed the
manufacturer’s protocol (Cat #: ARY005B, R&D Systems, Minneapolis, MN).
Biostatistics: All values are presented as means ± standard error (SEM). Statistical
analyses among two groups were performed using the Student’s t-test. Statistical
significance was set at p<0.05. Analysis was performed using Prism 8 (GraphPad
Software, San Diego, CA).
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2.3 Results
Adipose-derived stem/stromal cell differentiation, proliferation, and morphology is
consistent amongst young and aged.

Figure 2.1. Young and aged ASCs exhibit comparable morphology, differentiation
capacity. (A,B) Aged (A) and young (B) ASCs were maintained in stromal medium for
7 days, stained with Alexa Fluor 488 Phalloidin, and counterstained with DAPI. (C,D)
Adipogenic-differentiated aged (C) and young (D) ASCs were maintained 14 days in
adipogenic differentiation medium. Oil Red-O was used to stain for lipid rich vacuoles.
(E,F) Aged and young ASCs proliferation cultured in basal (E) and adipogenic (F)
medium was assessed at days 1, 3, 7, and 10 using the Cell Counting Kit-8 (CCK-8).

In order to determine the multi-lineage differentiation capacity of young and aged ASCs,
ASCs were differentiated into adipogenic lineages using lineage specific induction factors.
The number of aged ASCs capable of adipogenic differentiation parallel that of young
ASCs (Fig 2.1C and 2.1D). Phalloidin staining of aged and young ASCs showed no visible
difference in morphology (Fig 2.1A and 2.1B). To test the proliferation of young and aged
ASCs, ASCs were maintained in basal medium or differentiated into adipogenic lineages.
Proliferation of ASCs in basal (Fig 2.1E) and adipogenic (Fig 2.1F) was measured at days
1, 3, 7, and 10. Results revealed no significant difference in the proliferation of young and
aged ASCs in a stem or differentiated state.
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Adipose-derived stem/stromal cell extracellular matrix gene expression is not altered by
donor age.

Figure 2.2. Young ASCs displayed similar expression of matrix
compared to aged. Young and aged ASCs were cultured in basal
medium and collected at 80% confluence for qRT-PCR analysis.
Primers were chosen based on pooled young and aged ASC gene
expression and TCGA data. N=3 biological replicates. Mean value
represented by vertical bar.
To delineate differences between young and aged ASC extracellular matrix and
intracellular signaling gene expression, ASCs were maintained in basal medium until
attaining 80% confluency and collected for qRT-PCR analysis. There were no significant
changes in ECM gene expression observed in young ASCs. Many ECM genes examined
in qRT-PCR displayed high cycling and thus were no included the final analysis. Both
COL4A2 (10.95 +/- 10.62 SEM) and LAMA3 (6.82 +/- 4.72 SEM) were elevated in young
ASCs; however, expression was variable within each cohort (Fig 2.2).
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Age alters paracrine signaling of adipose-derived stem/stromal cells.

Figure 2.3 Young tumors and ASCs exhibit a comparable inflammatory profile. (A) Young and
aged ASC cytokine profile was assessed using cytokine array analysis. Young ASC cytokine
expression is normalized to aged, N=2. (B) Several genes significantly (p<0.05) elevated in young
ER-a+ tumors including CCL5, CD40L, IL-16, IL-32a, and SDF-1 paralleled expression exhibited
in young ASCs. GSM-CSF and IL-4 expression was diminished in young ER-a+ tumors, however
both were elevated in young ASCs. Young tumor gene expression is normalized to aged.

Since there were no observed differences in ASC matrix expression between young and
aged ASCs, we next sought to determine if paracrine factors were altered between young
and aged ASCs. To compare the production of paracrine factors from aged and young
ASCs, ASC cell supernates were collected, mixed with select antibodies, and incubated
on the array. Chemiluminescence results revealed elevated levels of proteins MCP-1,
CCL5, SDF-1, CD40, CXCL1, IFN-g, IL-8, IL-10, IL-16, IL-32a, and TNF-a in young ASC
conditioned media (Fig 2.3). Many of these paracrine factors are associated specifically
associated with the inflammatory phase of the wound healing process. Furthermore,
many of these are also elevated in young tumors, suggesting young ASCs display similar
responses to wounds and tumors (Table 2.1).
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Table 2.1 Comparison of young tumors and young ASC cytokine expression and their role
in wound healing.
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2.4 Discussion
Aging is characterized by both intrinsic and extrinsic changes to the human anatomy,
one in particular being modifications to the ECM. As a component of the
microenvironment, the ECM not only alters MSC behavior, but also undergoes ageassociated changes that are linked to multiple pathologies including cancer205. Although
it has been extensively shown that the ECM undergoes compositional changes with age,
results have been variable regarding the impact of age on MSC driven changes in ECM
composition. Uncertainty exists regarding age-related changes in MSC collagen
synthesis. Sun et al. found no difference in ECM total protein concentration synthesized
by aged and young murine bone marrow derived stem cells (BMSCs)206. Similarly, our
study shows no significant differences in ECM gene expression between aged and young
ASCs. Furthermore, ASCs cultured on fibronectin and laminin proteins revealed no
significant difference between aged and young. This suggests that age may not play a
role in ASC ECM deposition. This study also revealed similarities between aged and
young ASC proliferation and differentiation. Refuting evidence exists on the effect of age
on ASC differentiation and proliferation. Kornicka et al. and Choudhery et al. both
confirmed that ASC colony forming units (CFUs) and doubling time was affected by
age207, 208. In contrast, Dufrane et al. showed ASC expansion does not change based on
donor age. Khan et al. observed a decline in osteogenic potential in aged donors, whereas
Shi et al. reported no change with age43, 44. Pandey et al. also showed that ASCs from
younger donors had a significantly elevated potential to differentiate toward adipogenic
and osteogenic lineages189. These discrepancies suggest that a 2D platform may not
provide clinically relevant insight into the role aging plays on ASC behavior. Traditionally,
the hallmark of MSCs (and ASCs) was the ability to differentiate into various cell types for
regenerative repair of damaged tissue54, 209, 210. However, many studies suggest that the
treatment modality of MSCs occurs through the expression of cytokines and
chemokines211. Numerous studies have focused on the age-related changes in ASC
proliferation and differentiation; however, very few studies have delved into the effect of
age on ASC paracrine function. Our study has shown an elevated level of cytokine and
chemokine expression in young ASCs. Many of these factors including CXCL1, SDF-1,
CCL5, IL-8, IL-10, and TNF-a are associated with various phases of the wound healing
process. The ASC secretome has been harnessed as a cell-free treatment option for
many conditions including wound healing. Although studies have shown that ASC
paracrine activity has beneficial effects on non-healing wounds, evidence also indicates
the secretome presents adverse effects on pathologies including cancer. Furthermore,
no study to date has focused on the impact of ASC age on paracrine activity and its
influence on disease progression. Since there are observed differences in aged and
young ASC paracrine function, we will evaluate the extent to which those differences
influence the stromal environment of ER-a+ breast cancer tumors.
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CHAPTER 3. INVOLVEMENT OF STROMAL AGE IN BREAST CANCER
ESTROGEN SIGNALING
3.1 Introduction
In the United States, approximately 1 in 8 women will develop invasive breast
cancer212. The risk of breast cancer increases with age, a large percentage occurring in
women 50 and older. Fewer than 5% of breast cancers occur in women under the age of
40; however, breast cancer is the leading cause of cancer death amongst women
between 20-39 yo213. Roughly 11 per 100,000 breast cancer patients between the ages
of 15-39 years old have estrogen receptor-alpha (ER-a) positive tumors, making
endocrine therapy the treatment of choice. Although initially successful, many patients
develop resistance to treatment, resulting in the reappearance of cancer13. Young
individuals that have luminal ER-a+ breast cancer have an observed increase in
resistance to endocrine therapies such as tamoxifen214. Currently, there is neither specific
focus evaluating mechanisms for resistance to therapy in young ER-a+ patient
populations nor are current therapies designed to combat endocrine resistance evaluated
in young ER-a+ breast cancer patients214, 215. Recently, attention has been directed to
tumor microenvironment as an active participant in tumorigenesis and metastasis, as well
as the progression toward hormone independence and endocrine therapy resistance37,
216-218
. Tumors are composed of a diverse population of stromal cells such as ASCs,
endothelial cells, fibroblasts, adipocytes, and immune cells36, 219. The interaction between
tumor cells and the microenvironment can be characterized as reciprocal. This interplay
between normal cells, cancer cells, and the extracellular matrix contributes to the
hallmarks of cancer including immunomodulation, angiogenesis, invasion and
metastasis, and apoptotic resistance87. Similar to the wound healing process, the host
response leads not only to the modification of secreted proteins from tumor cells and
stroma, but also activates surrounding cells including ASCs220-224. ASCs, a multipotent
cell population found in breast tissue, are an integral part of the tumor microenvironment.
Although elicited for their multi-lineage differentiation and proactive role in tissue
regeneration, ASCs are linked to breast cancer progression54, 207, 219, 225, 226. ASCs
express and secrete multiple growth factors, cytokines, chemokines, and inflammatory
biomarkers such as SDF-1 and IGF-1 that aid in cancer development and progression168,
227, 228
. These signaling molecules also enhance breast cancer progression and regulate
resistance to endocrine therapies in ER-a+ breast cancer. Studies show that ASCs create
a pro-inflammatory tumor microenvironment that promotes tumorigenic activity through
the release of cytokines such as TNF-a, IL-6, and IL-8192. In addition, donor
characteristics alter the ASC phenotype. Specifically, ASCs derived from obese donors
are demonstrated as having elevated levels of LEP and contribute to endocrine resistance
in ER-a+ breast cancer through LEP.
The microenvironment or stem cell niche not only supports surrounding cell
populations, but also provides diverse biophysical and biochemical cues for regulating
cell behavior229. The ECM, a heterogeneous, non-cellular component of the
microenvironment, guides the behavioral patterns of stem cells including self-renewal,
quiescence, migration, differentiation, and apoptosis230-233. Aging of cells within this
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specialized microenvironment or age-dependent modifications in the acellular
components of the microenvironment can result in stem cell dysfunction234. As a
component of the microenvironment, the ECM also undergoes age-related changes that
compromises its mechanobiological role235. Studies have also shown that age-associated
changes in ECM composition subsequently alters stem cell behavior236. Although the
ECM alters the regenerative potential of stem cells, it is questionable as to whether or not
it is permanent. When aged MSCs are seeded young MSC-derived ECM, the aged MSCs
express greater pluripotency237. This further demonstrates the significance of the
microenvironment and its potential as a medium to rejuvenate aged stem cells.
Age-related changes in the ECM not only mediates cell proliferation, differentiation,
inflammation, and apoptosis, but also impacts the recruitment and functional integration
of ASCs236. As a result, processes such as wound healing become less effective. Wound
healing is a complex process involving the active participation of multiple cell types,
biochemical mediators, cytokines, growth factors, and ECM components238, 239. The
dynamics of a tumor parallel those of the wound healing process. Similar to a wound,
tumors attract a diverse population of stromal cells including stem cells and immune
cells219, 240. Although the stem cell response becomes damaging in light of tumor function
and progression, it contrastingly exhibits regenerative properties for chronic wounds241244
. Current research has yet to focus on the impact of stromal age on the development
of endocrine resistance. In the present study, we assessed the effect of ASC age on the
MCF-7 cell line in order to discover an underlying mechanism for the development of
endocrine resistance.
3.2 Materials and Methods
Cell culture: MCF-7 human breast adenocarcinoma cell line was maintained in Dulbecco’s
modified Eagle’s medium (DMEM, Cat #: 11965-092, Gibco, Waltham, MA)
supplemented with 10% fetal bovine serum (FBS, Cat #: SH30087.03, GE Healthcare),
1% Non-essential amino acids (NEAA, Cat #: 11140-050, Gibco), Minimal essential
amino acids (MEMAA, Cat #: 11130-051, Gibco), sodium pyruvate (100 mM, Cat #:
11360-070, Gibco), L-glutamine (Cat #:12561-056,, Gibco), Antibiotic-Antimycotic (AntiAnti, Cat #:15240062, Gibco), and insulin (4 mg/mL, Cat #: 12585-014, Gibco) at 37°C in
humidified 5% CO2. MCF-7 cells were seeded at 3,000 cells/cm2 in T150 flasks until
attained 80% confluence. Human adipose-derived stem/stromal cells (ASCs) were
obtained from Obatala Sciences and Dr. Frank Lau. Young donors (24-34 years old) and
aged donors (50-69 years old) were grouped by a specific age range (Table 1.5). Cultures
of ASCs (3,000 cells/cm2) were maintained with Alpha-MEM with L-glutamine (Cat #:
12561-056, Gibco) supplemented with 10% fetal bovine serum (FBS, Cat #: 43602-500,
JR Scientific) and 1% Antibiotic-Antimycotic (Anti-Anti, Cat #15240062, Gibco) until
attained 80% confluency. The procedure implemented for ASC expansion was described
previously by Bunnell et al204.
Conditioned media: ASCs were cultured until attaining 80% confluency in 10% AlphaMEM with L-glutamine (Cat #: 12561-056, Gibco) supplemented with 10% fetal bovine
serum (FBS, Cat #: 43602-500, JR Scientific) and 1% Antibiotic-Antimycotic (Anti-Anti,
Cat #15240062, Gibco). Cells were washed with sterile phosphate buffer saline (PBS,
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Cat #: 10010023, Gibco). ASCs were then cultured in phenol-free Dulbecco’s modified
Eagle’s medium (Cat #:31053-028, Gibco), 5% charcoal stripped FBS (Cat #:
SH3006803, GE Healthcare), 1% penicillin/streptomycin (P/S, Cat #: 15140-122, Gibco),
1% MEMAA, 1% NEAA, 1% Glutamax (Cat #: 35050-061, Gibco), and 1% sodium
pyruvate for 24 h. The conditioned media was collected, filtered, and stored at -20°C.
MCF-7 cells were treated with 0.25% Trypsin-EDTA (Cat #: 25200056, Gibco) and
seeded at 50,000 cells/cm2 in 10 cm dishes. Cells were maintained in 10% DMEM at
37°C in humidified 5% CO2 until 80% confluent. Once confluent, cells were maintained in
conditioned media obtained from aged and young ASCs for 72 h or 15 min. Cells were
then collected and stored at -80°C for RNA extraction and western blot analysis.
Proliferation Assay: MCF-7 cells were seeded at 50 cells/cm2 in 96-well plates. Cells were
maintained in 10% DMEM at 37°C in humidified 5% CO2 and treated with conditioned
media after 24 h. At days 0, 1, 5, and 7, cells were fixed with 95% methanol for 10 min.
They were washed 3x with PBS prior to crystal violet staining. Cells were stained with 3%
crystal violet solution and incubated at room temperature for 1 h. The wells were washed
with water then allowed to dry prior to imaging. After dissolving in 33% acetic acid,
absorption was determined at 595 nm using the Cytation 3.
Differentiation Assays: ASCs were cultured until attained 80% confluency in 10% AlphaMEM with L-glutamine supplemented with 10% FBS and 1% Anti-Anti. Adipogenic
differentiation medium (AdipoQual, Obatala Sciences, New Orleans, LA) was introduced
for 3 days and alternated with MCF-7 conditioned medium for 3 days for an 11-day period.
Cells were then collected and stored at -80°C for RNA extraction and qRT-PCR analysis.
Quantitative Real Time PCR (qRT-PCR): RNA was extracted from cell pellets using
QIAshredders (Cat #: 79656, Qiagen) and RNeasy Mini Kit (Cat #: 74106, Qiagen) as per
manufacturer instructions. Complementary DNA (cDNA) was synthesized using qScript
cDNA SuperMix (Cat #: 101414-106, VWR), and 1μg total RNA. Quantitative PCR was
performed using the BioRad iCycler (BioRad, v4.006) and Quanta SYBR green (VWR,
Radnor, PA) as per manufacture’s protocol. Expression was computed using the ΔΔ(Ct)
method using the reference gene GAPDH (ASCs) and b-Actin (MCF-7s). Primer
sequences are presented in Table S2. Normalization was to aged ASC gene expression
designated as 1.
Western blot analysis: MCF-7 cells were seeded at 50,000 cells/cm2 in 10 cm dishes.
Cells were maintained in 10% DMEM at 37°C in humidified 5% CO2 until 80% confluent.
At 80% confluency, 10% DMEM was removed and either 5% charcoal stripped media,
5% charcoal stripped media with estrogen (Cat #: E2758-1G, Sigma Aldrich, St. Louis,
MO, 1 µg/mL), or conditioned media from aged and young ASC donors was added to the
dishes. After 15 min at 37°C in humidified 5% CO2, the media was removed, cells were
washed, and cells were collected on ice and stored at -80°C. Cell pellets were lysed 100
μL of mammalian protein extraction reagent (M-PER, Cat #:78501, ThermoFisher
Scientific, Waltham, MA) supplemented with 1x Halt protease and phosphatase inhibitor
(Cat #:78444, ThermoFisher Scientific). BCA protein assays were run on the cell extracts
and 1µg of total protein was mixed with a master mix (Cat #:SM-W004, ProteinSimple,
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San Jose, CA) to give a final concentration of 0.2 mg/mL total protein. Samples were
heated at 95 °C for 5 min. Samples, blocking solution, primary antibodies (ER-α, Santa
Cruz # sc-543, 1:50; actin, Novus Biologicals # NB600-501H, 1:500; phospho-ER-α
serine 167, Cell Signaling #64508 1:25; phospho-ER-α serine 118, Cell Signaling #2511
1:25, phospho-ERK1/2, Cell Signaling #4307 1:25; total ERK, Cell Signaling #4695 1:50;
phospho-AKT, Cell Signaling #4060 1:25; total AKT, Cell Signaling #4691 1:50),
horseradish peroxidase-conjugated secondary antibodies (Cat#:DM-002, ProteinSimple),
chemiluminescent substrate (Cat #:DM-002, ProteinSImple), and separation and stacking
matrices (Cat #:SM-W004, ProteinSimple) were loaded into designated wells in a 384well plate according to the manufacturer’s instructions. After plate loading, fully automated
electrophoresis and immunodetection took place in the WES capillary system
(ProteinSimple). Proteins were separated by molecular weight at 375V for 25 min, and
primary and secondary antibodies incubated for 30 minutes. Chemiluminescence was
captured by a charge-coupled device camera, and the digital image analyzed using
Compass software (ProteinSimple). The amount of each protein was calculated based on
peak area. A virtual image is shown based on peaks from the electropherogram.
xCell Cell Type Enrichment Analysis: Immune and stromal cell infiltrate of young and aged
ER-a+ was analyzed using the xCell webtool. Ductal and lobular neoplasms were selected
from the case set of the TCGA-BRCA project (phs000178.v11.p8) derived from the NIH
Genomic Data Commons (GDC) Data Portal245. Based on the clinical information
provided with the TCGA-BRCA project, tumors were grouped into young (<45 years old)
and aged (>65 years old) categories. These selected cases were matched with precalculated TCGA data provided by the xCell webtool.
Breast cancer data sources and analysis: Invasive breast carcinoma data set
(IlluminaHiSeq) from The Cancer Genome Atlas (TCGA) research network was evaluated
for differences in gene expression between young and aged patients based on ER status.
Data base for Annotation, Visualization and Integrated Discovery v6.8 (DAVID v6.8) was
used to identify enriched functional-related gene groups found of interest in the TCGA
dataset246.The Breast Cancer Gene-Expression Miner v4.4 (bc-GenExMiner v4.4) was
used to perform an age-dependent comparison in gene expression of significant genes
from the TCGA data247. Original data analyzed in bc-GenExMiner was acquired from the
NCI GDC Data Portal248. The population selected was based solely on age, not receptor
status. The Kaplan-Meier Plotter was used to assess the effect of targeted genes on the
survival of ER-a+ breast cancer patients249. Cell enrichment analysis of young and aged
ER-a+ breast tumors was performed using the xCell webtool250.
Biostatistics: All values are presented as means ± standard error (SEM). Statistical
analyses among two groups were performed using the Student’s t-test. Statistical
significance was set at p<0.05. Analysis was performed using Prism 8 (GraphPad
Software, San Diego, CA).
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3.3 Results
Tumor micro-environment composition is altered in young ER-a+ breast cancer compared
to age.
According to the NCI Surveillance, Epidemiology, and End Results Program (SEER), HR+
breast cancer patients ages 15-39 years old have a lower survival rate (87.7%) compared
to ages 65-74 years old (95.6%) and 75+ years old (94.2%). To better identify
distinguishing features and underlying mechanisms for lower survival rates observed in
young ER-a+ patients, previously aligned and published data derived from The Cancer
Genome Atlas (TCGA) IlluminaHiSeq invasive breast cancer was analyzed for differences
between aged and young patient populations251-253. Tumor samples were separated
based on ER-a+ receptor status and age (young individuals <40 years old and aged
individuals >65 years old).

Figure 3.1. Tumor microenvironment is differentially regulated in young and aged ERa+ breast cancer patients. DAVID functional annotation tool was used to determine
enriched pathways of elevated genes in the TCGA data set. Results revealed
significant p values (p<0.05) for matrix, focal adhesion, cytokine, PI3K/AKT, and NFkB pathways. TCGA data was filtered based on fold changes ≧1.4.
Results demonstrated that key pathways enriched in young ER-a+ breast cancer samples
were those associated with the extracellular matrix (COL6A6, ITGA1, ITGA10, ITGA2,
ITGA4, LAMA1, LAMA2, LAMB3, LAMC1, LAMC2, LAMC3), focal adhesions, cytokinecytokine interactions (CCL19, CCL21, CCR4, CCR6, CXCL5, CXCL9, CD27, IL12B,
IL20), PI3K/AKT, and NF-kB (TNFRSF13B, TNFAIP3, TNFSF11) (Fig 3.1). Specifically,
tumors from young individuals had higher levels of matrix genes and these genes
correlated with poor patient survival.
In depth analysis of genes enriched in young (<40 years old) ER-a+ breast cancer
compared to aged ER-a+ (>65 years old) demonstrated that in addition to matrix,
increased cytokines associated with a pro-inflammatory phenotype (CCL5, IL12-B, IL-20,
IL-11, IL-19) and growth factors (FGF-1, PDGFB, SDF-1, IGF-1) were also detected. The
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increase in pro-inflammatory cytokines and growth factors suggests the tumors may be
eliciting support from surrounding cell types, specifically stem cells220, 254. Comparison of
breast tumor cell infiltration revealed significant differences (p<0.05) in CD8+ T-cells, Thelper 2 (Th2) cell, and M2 macrophages between young and aged ER-a+ breast tumors
(Fig 3.2A). Young tumors exhibited higher xCell scores for CD8+ T-cells (0.02± 0.003)
and Th2 cells (0.04 ± 0.004), but a lower score for anti-inflammatory M2 macrophages
(0.01 ±0.0008). In contrast to immune cell infiltration, both MSC and adipocyte xCell
scores were similar for young and aged ER-a+ breast tumors (Fig 3.2B).

Figure 3.2. Immune cell infiltrate differs between young and aged ER-a+ breast cancer
patients. (A) xCell cell type enrichment analysis of young (<45 years old) and aged (>65
years old) ER-a+ breast cancer patients revealed significant p values (p<0.05) for M2
macrophages, CD8+ T cells, and Th2 cells. Both CD8+ T cells and Th2 cells are enriched
in young tumors while M2 macrophages exhibit a lower quantity compared to aged. (B)
Both adipocytes and MSCs exhibit similar quantities in young and aged ER-a+ breast
tumors.

With an increase in specific stromal components in both the TCGA and enrichment data,
we next sought to determine the role of these specific components in patient survival.
Although selected genes exhibited increased expression in young in the TCGA data, they
were not individually associated with poor patient survival in the Kaplan Meier plots (Fig
3.3).
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Figure 3.3. High expression of targeted genes exhibits no impact on
patient survival. Kaplan Meier plots of elevated genes in young ER+ breast
tumors were used to evaluate the effect of expression on patient survival.
All plots displayed did not indicate a correlation between high expression
of targeted genes and poor patient survival.

Breast tumors exhibit age-dependent differences in specific stromal components.
The Breast Cancer Gene-Expression Miner (bc-GenExMiner) was used to evaluate the
age-dependent expression of genes linked to paracrine signaling. Targeted genes in age
groups <40 years old, 40-70 years old, and >70 years old were compared to determine
Significant differences in gene expression between 0-40 years old and 70-90 years old
was observed in CXCL1 and COL5A2. On the other hand, TCGA data comparing young
and aged HR+ tumors revealed significant differences in multiple genes (Table 3.1). Many
of these observed paracrine factors are pro-inflammatory, suggesting an inflammatory
response may play a role in the young patient tumor microenvironment.
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Table 3.1 Comparison of bc-Genex Miner and TCGA Paracrine Factor Expression in
Young Tumors.

bc-GenExMiner p-values represent the comparison between 0-40 and 70-90 years old.
TCGA p-values represent the comparison between <45 years old and >65 years old.
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Young stem cells induce endocrine response in ER-a+ breast cancer.

Figure 3.4. Young ASC secretome enhances MCF-7 proliferation. MCF-7 cells were
treated with CM from young or aged ASCs and proliferation via crystal violet was
evaluated at days 0, 1, 5, and 7. MCF-7 cells treated with young CM showed greater
proliferation through absorption (A) and visual staining (B).

Since age affects ASC paracrine signaling, we then assessed the effect of the ASC
*
secretome on ER-a+ breast cancer. To evaluate the effect of the secretome on
proliferation, MCF-7 cancer cells were treated with CM obtained from aged and young
ASCs. Crystal violet staining revealed increased proliferation of MCF-7 cells treated with
CM from young ASCs (684.5 +/-69.78 SEM) compared to those treated with aged CM
(480.4 +/-158.2 SEM) at day 7(Fig 3.4). The proliferation of MCF-7 cells treated with
young, CM showed significant change from day 1 to day 7 (p<0.05) whereas those treated
with aged, conditioned medium showed no significance in proliferation. To determine if
the increased proliferation was mediated through endocrine signals, ER-a response
genes were evaluated via qRT-PCR. Results show that the ER-a regulated genes PGR
and SDF-1 were increased by 1 (+/- 0.44 SEM) and 1.25 (+/- 0.35 SEM) respectively in
MCF-7 cells treated with young
ASC CM when compared to those treated with aged CM (Fig 3.5). Protein expression of
upstream ER-a regulators and their ER-a phosphorylation sites was evaluated to further
determine the role of the ASC secretome on MCF-7 endocrine signaling. After stimulation
with conditioned medium for 15 min, MCF-7 cells were collected for western blot analysis.
Results revealed an increase at p-ER S167 in MCF-7 cells exposed to young CM,
suggesting that ASC signaling is mediated through the estrogen receptor. To confirm
these results, MCF-7 cells were treated with tamoxifen for 4h prior to stimulation with
aged or young CM. Cell were collected after 24h and ER-a response genes were
evaluated with qRT-PCR. While elevated in the presence of young CM, ER-a shows loss
of signal in the presence of tamoxifen. These results suggest that ER-a plays a key role
in stem cell signaling. To further validate the effect of stem cell signaling on ER-a activity,
MCF-7 cells were treated with aged and young CM followed by treatment with adipogenic
differentiation media for 11 days. qRT-PCR results revealed no difference in gene
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expression of ER-a, PGR, and SDF-1 between aged and young. The loss of stemness
and commitment to an adipogenic phenotype results in comparable ER-a expression in
aged and young.

Figure 3.5. Young ASC secretome enhances estrogen signaling in MCF-7 cell lines. (A) MCF-7
cells were cultured with young and aged ASC CM and collected for qRT-PCR. Both PGR and
SDF-1 expression were significantly different (p<0.05) from aged expression. (B) MCF-7s were
cultured with young and aged ASC CM and evaluated for total and phosphorylated AKT, ERK,
and ER protein expression using Western blot analysis. Results show an increase at p-ERS167 in MCF-7s stimulated with young CM. (C) MCF-7 cells were treated with tamoxifen 4 h
before being treated with either young or aged ASC CM. MCF-7 cells were collected after 24 h
for qRT-PCR to evaluate ER regulated gene expression. Results confirm that ASC signaling is
mediated by ER. (D) Differences in gene expression between young and aged is lost with
adipogenic differentiation.
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3.4 Discussion
The microenvironment plays a pivotal role in directing cell behavior. Strong evidence
supporting the significance of the microenvironment on cell behavior is demonstrated in
heterochronic parabiosis studies. The breast cancer microenvironment is defined as a
combination of cells within the tumor and its stroma, the ECM, and surrounding signaling
molecules255. In recent years, an overwhelming amount of evidence supports that the
tumor microenvironment, and more specifically components of the ECM, contribute to
breast cancer progression and metastasis205, 256-262. Furthermore, studies have shown
that the tumor microenvironment actively participates in the progression toward hormone
independence and endocrine therapy resistance69, 216, 263. Age-related physical and
compositional changes in the ECM is linked to tumor progression264. Although it is welldocumented that specific extracellular matrix gene profiles are associated with the
prognosis and treatment of breast cancer, little evidence is known about how local cellular
function, specifically the ASC secretome, contributes to endocrine resistance in young
ER-a+ breast cancer patients264-268. The extent to which ASCs, a resident of the breast
cancer microenvironment, affect breast cancer progression and response to treatment
has yet to be fully elucidated. Previous studies indicate that ASC age has no bearing on
ECM dynamics. Although active in ECM production, ASCs also have both a paracrine
and immunomodulatory function. In regenerative medicine, ASCs are no longer solely
used for cell restoration. Their secretion of trophic factors has been harnessed as a viable
approach for tissue regeneration. Although beneficial in terms of regenerative medicine,
the paracrine actions of ASCs may enable tumor formation, growth, and maintenance.
The expression of paracrine factors between young and aged BC tumors is strikingly
different. Chemokines including CXCL1 and IL-8 both exhibited elevated expression in
young ASCs in the cytokine array analysis. Increased CXCL1 protein expression is
associated with increased tumor growth and pulmonary metastasis in MDA-MB-231
breast cancer cells269. Furthermore, increased expression of CXCL1 RNA is associated
with a decreased survival of patients with ER-a+ breast cancer270. IL-8, a pro-inflammatory
chemokine that promotes neutrophil chemotaxis and degranulation, is typically
upregulated in breast cancer and associated with poor prognosis271. The monocyte
attracting chemokine CCL5 was also upregulated in young ASCs. Studies have shown
that an overexpression of CCL5 in breast tumor cells results in increased invasiveness272.
SDF-1, a chemokine naturally secreted by MSCs, is an important mediator of MSC
chemotaxis and primary breast tumorigenesis68, 217. SDF-1, another cytokine elevated in
young ASCs, has been shown to promote hormone independent growth in the hormone
dependent MCF-7 line70. As an ER-a-regulated gene, SDF-1 is suggested to play a role
in the progression of breast carcinoma cells273, 274. The amount of SDF-1 secretion by
MSCs has shown variance based on microenvironmental factors, one of which could be
age275, 276. SDF-1 signaling also contributes to chemotherapy resistance in cancer cells
by modulating survival pathways such as AKT, NOTCH, and the BCL-2 family277, 278.
Although tumor expression of specific cytokines, chemokines, and growth factors is
correlated with poor patient survival, Kaplan Meier plots of TNF-a, IL-16, IL-32, SDF-1,
IGF-1, and CD27 do not reflect those same findings. Rather than examining singular
genes, further analysis these genes and patient survival must be performed using gene
signature cohorts or groups of genes.
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Figure 3.6. Young ER-a breast tumor stroma exhibits significant differences in specific
matrix components and immune cell types. (A) Young tumor stroma (<45 years old)
revealed significantly higher levels of matrix components (fibronectin, integrin a and b,
collagen III, collagen V, collagen VI, collagen VII, and laminins A, B, and C) and immune
cell types (CD8+ T cells and Th2 cells) (p<0.05). (B) Aged tumor stroma (>65 years old)
revealed a significantly higher M2 macrophage infiltrate (p<0.05) compared to young
stroma. The young and aged tumor stroma exhibit comparable numbers for MSC and
adipocyte infiltrate; however, young MSCs may exhibit a greater potency and stimulate
a rapid estrogen signaling pathway via cytokine and growth factor secretions. This
contributes to the increased ER-a signaling and increased proliferation observed in
MCF-7 cells stimulated with young CM compared to those stimulated with aged CM.

Breast cancer is composed of a large cellular array: ASCs, adipocytes, fibroblasts,
immune cells, and endothelial cells. The analysis of cell infiltrate in young and aged breast
tumors has revealed significant differences between several immune cell populations
including CD8+ T cells, M2 macrophages, and Th2 (Fig 3.6A and B). Previous studies
have shown that CD8+ T cells, T-helper 1 (Th1) cells, M1 macrophages, and natural killer
(NK) cells exhibit anti-tumor activities, whereas T-regulatory (Treg) cells and M2
macrophages exhibit immune-inhibitory, pro-tumor activities279. Interestingly, M2
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macrophage infiltrate was significantly lower in young compared to aged tumors, and
CD8+ T cells were significantly higher in young compared to aged tumors. Although Jin
and Hu determined that CD8+ T cells are associated with disease-free survival in young
breast cancer patients compared to aged, Ali et al showed that CD8+ T cells infiltrate
predicts a more favorable outcome for ER- tumors than ER+ tumors280, 281. Based on the
literature, there is still no conclusive evidence identifying significant biological differences
and T-cell immune infiltration between young and aged ER+ breast cancer patients281.
With discrepancies in immune cell infiltration as prognostic indicators, other stromal cells
have been exploited as possible prognostic indicators for breast cancer. Although MSC
infiltration in young and aged breast tumors were not significantly different, MSCs may
influence age-dependent tumorigenesis in an alternative manner. Rather than directly
infiltrating the tumor, it is suggested that MSCs prime the site for tumor cell growth via
secretion of high levels of multiple growth factors, cytokines, and chemokines70. Younger
patients may have MSCs that secrete higher volumes of pro-tumorigenic factors
compared to aged, thus resulting in poor prognoses in young patients with specific
subtypes including ER+ and TNBC. Patient age correlates with stem cell potency,
inflammatory secretion, and differentiation capacity189, 207, 282. Studies on BMSCs noted
that aged stem cells had a lack of receptors for cytokines and chemokines, including
TNFR and loss of these receptors resulted in an inability to respond to immune signals
from the surrounding environment283. Together this suggests that young stroma,
specifically young ASCs, may be more reactive to cytokine signals in a tumor environment
than aged stroma. Prior studies evaluating differences in young and aged ASCs
demonstrate that young ASCs have increased levels of pro-inflammatory signaling (MCP1, IL-8, TNF-a) and adipogenic markers (PPARg) compared to aged ASCs284. TNF-a is
critical for ER-a+ breast cancer progression and released in response to estrogen
stimulation284, 285.
TNF-a is not only secreted by tumor cells, but is also produced by ASCs. TNF-a
production by tumors has been linked with poor prognosis and loss of hormone
responsiveness286. The interaction of TNF-a with TNFRs activates downstream targets
including the pro-inflammatory transcription factor NF-kB. NF-kB consists of a family of
transcription factors that contribute to inflammation, immunity, cell proliferation,
differentiation, and survival. The interaction of NF-kB with ER-a is one of the mechanisms
of estrogen signaling. ER-a acts through several different mechanisms. Direct genomic
signaling is the traditional mechanism of estrogen signaling. The binding of the dimerized
estrogen receptors leads to nuclear translocation and binding to estrogen response
elements (EREs) sequences of target genes12. Estrogen can also induce rapid, nongenomic signaling in which estrogen induces gene transcription and protein synthesis by
alternative mechanisms. The activation of signaling cascades including the PKC pathway,
RAS/RAF/MAPK pathway, PI3K/AKT pathway, and the cAMP/PKA pathway leads to
subsequent activation and binding of a variety of transcription factors (i.e. C/EBPb, NFkB, STAT) to alternative DNA response elements12, 16-21. Adding to the complexity of
estrogen signaling, estrogen receptors can also be activated in the absence of estrogens
or other receptor agonists22. Ligand-independent estrogen receptor activation occurs via
the phosphorylation of specific residues (i.e. serine or tyrosine) in the receptors
themselves or by coregulators such as PKA, MAPK, PKC, inflammatory cytokines (i.e. IL2), and peptide growth factors (i.e. IGF-1, TGFb, EGF). Evidence has demonstrated that
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the crosstalk between ER-a and many of the aforementioned growth factors and
inflammation-associated transcription factors including NF-kB results in acquired
endocrine resistance287-295.
Although ER-a has been shown to repress the transcriptional activity of NF-kB,
reports have also exhibited the existence of positive crosstalk between ER-a and NFkB296-298. Studies have shown that constitutive activation of NF-kB in breast tumors is
correlated with more aggressive ER-a+ tumors, the development of resistance to
endocrine therapy, and progression to estrogen-independent growth299-303. It has also
been reported that cytokines and chemokines released in the cancer-induced
inflammatory environment activates NF-kB-associated pathways that desensitize SERM
response304. Long term antihormonal therapy alters ER-a driven regulation of metabolism
and inflammation which also results in the constitutive activation of NF-kB305-307. The
constitutive activation of the canonical NF-kB pathway is not only triggered by ER-a, but
also by TNF-a. TNF-a activation of NF-kB results in the transcription of cytokines
including IL-8, IL-1b, and a positive feedback loop resulting in NF-kB dependent TNF-a
production33. Both IL-8 and TNF-a exhibit increased expression in both young ASCs and
tumor samples from young breast cancer patients. As previously mentioned in section
1.4, NF-kB expression is elevated in older donors; however, commonly associated
molecules including IL-1a, TNF-a, iNOS, IL-8, and IkB were significantly downregulated
in older donors189. Furthermore, older donors exhibited elevated concentrations of NF-kB
in the cytosol whereas younger donors displayed an accumulation of NF-kB in the
nucleus. An accumulation of NF-kB subunits in the cytosol suggests decreased
transcriptional activity, thus verifies the decreased pro-inflammatory cytokines and
molecules observed in older donors.
A link between ER-a and NF-kB possibly lies at the Serine 167 (Ser-167) residue
on ER-a. NF-kB is normally sequestered in the cytoplasm of most cells and bound to the
inhibitory proteins IkB. IkB kinase a (IKKa) phosphorylates IkB proteins, leading to the
degradation and subsequent activation of NF-kB gene expression. A study by Bennett
et al. has shown that increased IKKa levels correlate with reduced cancer-specific
survival and reduced recurrence-free survival in ER+ breast cancer308. In addition to IKKa,
the non-canonical kinase IKKe has been identified as an important mediator of
inflammatory and oncogenic signaling. IKKe as a breast cancer oncogene has been
amplified and overexpressed in over 30% of breast carcinomas and breast cancer cell
lines309. It has been shown that IKKe phosphorylates Ser-167 of ER-a, and activation of
ER-a contributes to tamoxifen resistance in breast cancer. Western blot analysis results
from this study indicate increased expression of p-SER-167 in MCF-7 cells stimulated
with young ASC conditioned media. Ser-167 is located within the hormone-independent
transcriptional activation function 1 (AF-1) region, suggesting the phosphorylation of this
site behaves independently of estrogen-ER-a interactions310, 311. Future studies should
further explore the role of the NF-kB pathway on ASC-mediated estrogen-independent
signaling in young ER-a+ breast cancer patients.
In addition to TNF-a, CD40 ligand (CD40L) may contribute to the onset of
endocrine resistance. CD40L, an activator the noncanonical NF-kB pathway, showed
elevated expression in young patient tumors. CD40L binding to its receptor CD40 results
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in the transcription of SDF-1, a cytokine that is elevated in both young patient tumors and
young ASCs. In addition to TNF-a, CD40L expression may have an underlying role in NFkB activation and subsequent endocrine resistance in young ER-a+ breast cancer
patients.
Through this study, we have observed that the ASC secretome enhances estrogen
independent signaling in the ER-a+ MCF-7 cell line. There is also limited evidence that
the aged ASC secretome impacted MCF-7 cells in a manner comparable to the young
ASC secretome.
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APPENDIX A. SUPPLEMENTAL TABLES
Table S1. Young and aged ASC donor demographics.
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Table S2. qRT-PCR oligonucleotide primers.
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